4 Results for "

NSG+mice

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "NSG+mice" in MCE Product Catalog:

Foralumab
Foralumab
0 Images
Cat. No.: HY-P99199
CAS No.: 946415-64-1
Synonyms: NI-0401

Target:  

CD3

Research Areas:  

Neurological Disease Metabolic Disease

Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
Bavunalimab
Bavunalimab
0 Images
Cat. No.: HY-P99354
CAS No.: 2329669-78-3
Synonyms: Anti-Human CTLA4xLAG3; XmAb-22841; Pavunalimab

Target:  

LAG-3

Research Areas:  

Inflammation/Immunology Cancer

Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
PI4K-IN-3
PI4K-IN-3
0 Images
Cat. No.: HY-178775
Target:  

PI4K Parasite MAP4K PI3K

Research Areas:  

Infection

PI4K-IN-3 (Compound 27) is an orally active PI4K inhibitor with an IC50 of 1.9  nM for Plasmodium vivax PI4K. PI4K-IN-3 has no hERG channel inhibition and mammalian cytotoxicity. PI4K-IN-3 has significant selectivity against the human MINK1 and MAP4K4 kinases but with low selectivity against human PI3Kα and PI4Kβ. PI4K-IN-3 has potent antimalarial activity and significantly reduces parasitaemia in NSG mice mouse models of Plasmodium falciparum malaria .
FLT3-IN-28
FLT3-IN-28
0 Images
Cat. No.: HY-170576
Target:  

FLT3 STAT Apoptosis

Research Areas:  

Cancer

FLT3-IN-28 (Compound 12y) is an orally active FLT3 inhibitor with antitumor activity. FLT3-IN-28 selectively inhibits cancer cells harboring the FLT3 internal tandem duplication (ITD) mutation, with IC50 values of 85, 290, 130, 65, and 220 nM for BaF3-FLT3-ITD, BaF3-TEL-VEGFR2, MV4-11, MOLM-13, and MOLM-14 cell lines respectively (MV4-11 and MOLM-13/14 are acute myeloid leukemia (AML) cell lines carrying the FLT3-ITD mutation). Additionally, FLT3-IN-28 can downregulate the phosphorylation levels of FLT3 and STAT5 in MOLM-13 cells and induce cell cycle arrest and Apoptosis. FLT3-IN-28 has an oral bioavailability of 19.2% in SD rats and can prolong survival in a dose-dependent manner in NSG mice xenografted with MOLM-13 cells. FLT3-IN-28 holds promise for research in cancer fields related to FLT3-ITD .
Assay Types